A decade-long study tracking patients with aggressive blood cancers has revealed that CAR T-cell therapy can lead to long-term remission for a significant portion of individuals. Approximately one-third of patients with aggressive non-Hodgkin lymphoma remained cancer-free ten years after a single CAR T infusion, while nearly half of those with a slower-growing form achieved similar outcomes. This breakthrough offers hope for a potential cure, moving beyond traditional treatments towards living, programmable therapies that could redefine cancer care. AI
RANK_REASON Research findings on the long-term efficacy of a medical therapy. [lever_c_demoted from research: ic=1 ai=0.1]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
